Harnessing Biased Signaling to Enhance Incretin Pharmacodynamics
Time: 8:30 am - 9:00 am
day: Day One
Details:
- Developing GLP-1 receptor agonists that preferentially activate pathways leading to enhanced glucose-dependent insulin secretion while minimizing pathways associated with adverse effects
- Approaches for accurately assessing incretin pharmacodynamics in humans
- Utilizing biased signaling to achieve personalized medicine
